WAINUA (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Wainua (autoinjector), and what generic alternatives are available?
Wainua (autoinjector) is a drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this drug.
This drug has two hundred and thirty-four patent family members in thirty-five countries.
The generic ingredient in WAINUA (AUTOINJECTOR) is eplontersen sodium. One supplier is listed for this compound. Additional details are available on the eplontersen sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Wainua (autoinjector)
Wainua (autoinjector) will be eligible for patent challenges on December 21, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WAINUA (AUTOINJECTOR)?
- What are the global sales for WAINUA (AUTOINJECTOR)?
- What is Average Wholesale Price for WAINUA (AUTOINJECTOR)?
Summary for WAINUA (AUTOINJECTOR)
International Patents: | 234 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | WAINUA (AUTOINJECTOR) at DailyMed |
US Patents and Regulatory Information for WAINUA (AUTOINJECTOR)
WAINUA (AUTOINJECTOR) is protected by four US patents and two FDA Regulatory Exclusivities.
Patents protecting WAINUA (AUTOINJECTOR)
Compositions and methods for modulating TTR expression
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
Modulation of transthyretin expression
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Conjugated antisense compounds and their use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Conjugated antisense compounds and their use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting WAINUA (AUTOINJECTOR)
TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for WAINUA (AUTOINJECTOR)
See the table below for patents covering WAINUA (AUTOINJECTOR) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 631537 | Compositions and methods for modulating apolipoprotein c-iii expression | ⤷ Sign Up |
Japan | 2021107408 | ⤷ Sign Up | |
South Korea | 20230113835 | ⤷ Sign Up | |
Costa Rica | 20150612 | COMPOSICIONES Y MÉTODOS PARA MODULAR LA EXPRESIÓN DE TTR Y VHB | ⤷ Sign Up |
Israel | 284593 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |